[go: up one dir, main page]

MX343165B - Agonistas del receptor 5-ht4 para el tratamiento de demencia. - Google Patents

Agonistas del receptor 5-ht4 para el tratamiento de demencia.

Info

Publication number
MX343165B
MX343165B MX2012009211A MX2012009211A MX343165B MX 343165 B MX343165 B MX 343165B MX 2012009211 A MX2012009211 A MX 2012009211A MX 2012009211 A MX2012009211 A MX 2012009211A MX 343165 B MX343165 B MX 343165B
Authority
MX
Mexico
Prior art keywords
dementia
treatment
compound
formula
pharmaceutically acceptable
Prior art date
Application number
MX2012009211A
Other languages
English (en)
Other versions
MX2012009211A (es
Inventor
Take Yukinori
Ohshiro Hiroyuki
Fujiuchi Akiyoshi
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of MX2012009211A publication Critical patent/MX2012009211A/es
Publication of MX343165B publication Critical patent/MX343165B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere a un compuesto de fórmula (I) o una sal farmacéuticamente aceptable de éste con actividades agonistas al 5-HT4, el cual es útil en el tratamiento de la demencia. Esta invención también se refiere a una composición farmacéutica para el tratamiento de la demencia y la cual comprende una cantidad terapéuticamente efectiva de un compuesto de fórmula (I) o una sal farmacéuticamente aceptable de éste. Además esta invención se refiere a un método para el tratamiento de la demencia en un sujeto animal, incluyendo un sujeto mamífero, el cual comprende la administración al sujeto animal, incluyendo un sujeto mamífero, de un compuesto de fórmula (I) o una sal farmacéuticamente aceptable de éste. (ver fórmula (I)).
MX2012009211A 2010-02-12 2011-02-14 Agonistas del receptor 5-ht4 para el tratamiento de demencia. MX343165B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28243210P 2010-02-12 2010-02-12
PCT/JP2011/000793 WO2011099305A1 (en) 2010-02-12 2011-02-14 5-ht4 receptor agonists for the treatment of dementia

Publications (2)

Publication Number Publication Date
MX2012009211A MX2012009211A (es) 2012-09-07
MX343165B true MX343165B (es) 2016-10-26

Family

ID=44367591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009211A MX343165B (es) 2010-02-12 2011-02-14 Agonistas del receptor 5-ht4 para el tratamiento de demencia.

Country Status (11)

Country Link
US (1) US8980922B2 (es)
EP (1) EP2533780B1 (es)
JP (1) JP6023926B2 (es)
KR (1) KR101737388B1 (es)
CN (2) CN107260736A (es)
BR (1) BR112012020060B8 (es)
CA (1) CA2789663C (es)
ES (1) ES2640752T3 (es)
MX (1) MX343165B (es)
RU (1) RU2569733C2 (es)
WO (1) WO2011099305A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2906217A1 (en) * 2012-10-11 2015-08-19 Grünenthal GmbH Treatment and/or prophylaxis of tspo mediated diseases and/or disorders
DK2976337T3 (en) 2013-03-20 2018-07-16 Suven Life Sciences Ltd 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists
FR3006686A1 (fr) * 2013-06-05 2014-12-12 Univ Caen Composes inhibiteurs de l'acetylcholinesterase et agonistes des recepteurs serotoninergiques 5ht4, a effet promnesiant, leurs procedes de preparation et compositions pharmaceutiques les contenant
CN105873920B (zh) * 2013-12-16 2018-06-08 苏文生命科学有限公司 作为5-ht4受体激动剂的吲唑化合物
DK3265459T3 (da) 2015-02-13 2019-07-15 Suven Life Sciences Ltd Amidforbindelser som 5-ht4-receptoragonister
JP6900028B2 (ja) * 2017-03-29 2021-07-07 国立大学法人帯広畜産大学 パーキンソン病に併発した認知障害の治療剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5864039A (en) 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
EP0873990A1 (en) * 1995-09-22 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and medicinal use thereof
MY134008A (en) 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
KR100856622B1 (ko) 2001-01-22 2008-09-03 메모리 파마슈티칼스 코포레이션 포스포디에스테라제 4 억제제
EP1383767A1 (en) 2001-02-08 2004-01-28 Memory Pharmaceutical Corporation Trifluoromethylpurines as phosphodiesterase 4 inhibitors
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
WO2004026868A1 (en) 2002-09-20 2004-04-01 Pfizer Japan Inc. N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
GB0313772D0 (en) 2003-06-13 2003-07-23 Merck Sharp & Dohme Therapeutic treatment
PT1664036E (pt) * 2003-09-03 2012-02-16 Pfizer Compostos de benzimidazolona que possuem actividade agonística do receptor 5-ht4
WO2005049608A1 (en) * 2003-11-24 2005-06-02 Pfizer Japan, Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
ATE388146T1 (de) * 2004-01-29 2008-03-15 Pfizer 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
MXPA06014486A (es) 2004-06-15 2007-03-01 Pfizer Derivados de acido carboxilico de bencimidazolona.
JP4129445B2 (ja) * 2004-06-15 2008-08-06 ファイザー・インク ベンズイミダゾロンカルボン酸誘導体
JP2008509088A (ja) * 2004-09-02 2008-03-27 ファイザー株式会社 ベンズイミダゾロンカルボン酸誘導体
NZ556627A (en) 2005-02-22 2010-09-30 Pfizer Oxyindole derivatives as 5HT4 receptor agonists
GB0526258D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0603550D0 (en) * 2006-02-22 2006-04-05 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
BR112012020060B1 (pt) 2021-05-11
ES2640752T3 (es) 2017-11-06
CA2789663A1 (en) 2011-08-18
RU2569733C2 (ru) 2015-11-27
CA2789663C (en) 2018-10-02
US20120322826A1 (en) 2012-12-20
RU2012139034A (ru) 2014-03-20
EP2533780A4 (en) 2015-04-08
MX2012009211A (es) 2012-09-07
US8980922B2 (en) 2015-03-17
JP2013519630A (ja) 2013-05-30
EP2533780B1 (en) 2017-08-23
KR101737388B1 (ko) 2017-05-18
CN107260736A (zh) 2017-10-20
BR112012020060B8 (pt) 2021-05-25
BR112012020060A2 (pt) 2016-05-10
WO2011099305A1 (en) 2011-08-18
EP2533780A1 (en) 2012-12-19
KR20130035999A (ko) 2013-04-09
JP6023926B2 (ja) 2016-11-09
CN102753172A (zh) 2012-10-24

Similar Documents

Publication Publication Date Title
PH12012501800A1 (en) 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
MX341482B (es) Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MX2011011028A (es) Agonista del receptor beta de hormona tiroidea novedoso.
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
IN2014MN02106A (es)
EA201300869A1 (ru) Морфинановые соединения
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
MX2013012588A (es) Inhibidores de cinasa.
MY169479A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
MX2015013328A (es) Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartilago.
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
MX2010009462A (es) Derivados de indazol.
BR112012023178A2 (pt) ramidinas substituídas como antagonistas de receptor prostaglandina 2
MX343165B (es) Agonistas del receptor 5-ht4 para el tratamiento de demencia.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
EA201391524A1 (ru) Производные гликозида и их применение
MX2013006768A (es) Moduladores de receptor de glucagon.
IN2013DN02555A (es)
PH12012501843A1 (en) Novel benzamide derivatives
MX353991B (es) Agonista del receptor de 5-ht4 como agente procinetico.
IN2014KN01113A (es)
PH12013500671A1 (en) Novel gpr 119 agonists

Legal Events

Date Code Title Description
FG Grant or registration